COR2ED - Oncology Medical Conversation15 Okt

Metastatic TNBC cannot wait

In this video podcast, Prof. Giuseppe Curigliano and Dr Javier Cortés explore how TROP2-directed antibody–drug conjugates (ADCs) are shaping 1st line treatment for metastatic triple-negative breast cancer (TNBC).

Key clinical takeaways:

Earlier placement: TROPION-Breast02 and ASCENT-03 support 1st line TROP2 ADC use in defined patients who are not candidates for an ICI; ASCENT-04 supports SG plus pembrolizumab in the studied PD-L1-positive population

Individualised selection: Apply each trial to the appropriate patient. Consider disease characteristics, prior therapy, schedule and AE profile; avoid indirect comparisons between Dato-DXd and SG

Proactive safety: Translate the Dato-DXd and SG safety evidence into treatment-specific prevention, monitoring and escalation plans before dose 1

You can also watch a video of the experts in conversation and download the accompanying transcript on our website: https://cor2ed.com/breast-cancer-connect/programmes/metastatic-tnbc

Or watch on YouTube: https://youtu.be/3gr7g_IeRtU

LinkedIn: https://www.linkedin.com/company/breastcancerconnect/home/

X: https://x.com/BreastCaConnect

Instagram: https://www.instagram.com/cor2edmeded 

Subscribe to this channel to stay up to date with new medical education programmes as they’re released.

This content is intended for healthcare professionals only.

This podcast is supported by an Independent Education Grant from AstraZeneca

This podcast is developed by cor2ed.com

Published on October 2026

Det här avsnittet är hämtat från ett öppet RSS-flöde och publiceras inte av Podme. Det kan innehålla reklam.

Avsnitt(91)

Pre-analytical phase challenges and biomarker testing in HER2+ metastatic breast cancer

Pre-analytical Phase Challenges and Biomarker Testing in HER2+ Metastatic Breast Cancer Key clinical takeaways: Metastatic breast cancer (mBC) is a complex, heterogeneous disease requiring multi...

12 Mars 23min

Metastatic breast cancer: Understanding HER2-low and HER2-ultralow classification

Understanding HER2-low and HER2-ultralow classification in mBC In this video podcast moderated by the Oncology Brothers, Dr Komal Jhaveri provides a practical overview of how this shift beyond a binar...

17 Dec 202525min

Understanding EP-NEC: Through Diagnosis, Treatment, and Support

In this podcast, Medical Oncologist, Dr Aman Chauhan and Neuroendocrine Patient Advocate, Susan Meckler-Plummer, discuss extrapulmonary high-grade neuroendocrine carcinomas (EP-NECs), a rare, aggressi...

7 Nov 202527min

Exploring the role of targeted radiopharmaceutical treatment in NETs

How are advances in radioligand therapy shaping the treatment of neuroendocrine tumours, and what does recent trial evidence tell us? What are the key considerations for patient selection, sequencing,...

30 Sep 202521min

Tackling mPDAC: chemotherapy strategies that matter

Metastatic pancreatic ductal adenocarcinoma (mPDAC) is notoriously aggressive with a poor prognosis. It is often diagnosed late, and by this time, surgery is usually not an option. Median overall surv...

19 Maj 202521min

Understanding Rare NSCLC Mutations: Insights, access and support

Listen to a revealing conversation between Dr Joshua Sabari, a Medical Oncologist specialising in the treatment of rare alternations of NSCLC and Debra Montague, President of Lung Cancer Europe (LuCE)...

14 Maj 202520min

The HER2 diagnostic and treatment landscape in NSCLC

Episode 2: Navigating common treatment scenarios in HER2-mutant NSCLC This is the second episode of a two-part series on the HER2 diagnostic and treatment landscape in NSCLC, hosted by the Oncology B...

28 Apr 202518min